Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. / Busch, Nikolaj; Jensen, Magnus T.; Goetze, Jens P.; Schou, Morten; Biering-Sørensen, Tor; Fritz-Hansen, Thomas; Andersen, Henrik U.; Vilsbøll, Tina; Rossing, Peter; Jørgensen, Peter G.

I: Journal of Diabetes, Bind 13, Nr. 9, 2021, s. 754-763.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Busch, N, Jensen, MT, Goetze, JP, Schou, M, Biering-Sørensen, T, Fritz-Hansen, T, Andersen, HU, Vilsbøll, T, Rossing, P & Jørgensen, PG 2021, 'Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes', Journal of Diabetes, bind 13, nr. 9, s. 754-763. https://doi.org/10.1111/1753-0407.13172

APA

Busch, N., Jensen, M. T., Goetze, J. P., Schou, M., Biering-Sørensen, T., Fritz-Hansen, T., Andersen, H. U., Vilsbøll, T., Rossing, P., & Jørgensen, P. G. (2021). Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. Journal of Diabetes, 13(9), 754-763. https://doi.org/10.1111/1753-0407.13172

Vancouver

Busch N, Jensen MT, Goetze JP, Schou M, Biering-Sørensen T, Fritz-Hansen T o.a. Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. Journal of Diabetes. 2021;13(9):754-763. https://doi.org/10.1111/1753-0407.13172

Author

Busch, Nikolaj ; Jensen, Magnus T. ; Goetze, Jens P. ; Schou, Morten ; Biering-Sørensen, Tor ; Fritz-Hansen, Thomas ; Andersen, Henrik U. ; Vilsbøll, Tina ; Rossing, Peter ; Jørgensen, Peter G. / Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. I: Journal of Diabetes. 2021 ; Bind 13, Nr. 9. s. 754-763.

Bibtex

@article{eac81ada9da5468092415f74f687e9b6,
title = "Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes",
abstract = "Background: Diagnostic tests including echocardiography, albuminuria, electrocardiogram (ECG), high-sensitivity troponin I (hs-TnI), and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been suggested as cardiovascular (CV) risk predictors in type 2 diabetes. We studied the separate and combined prognostic yield of these risk markers. Methods: In all, 1030 patients with type 2 diabetes were recruited from specialized clinics in this prospective cohort study. Full echocardiographic evaluation was feasible in 886 patients in sinus rhythm with adequate image quality. ECG was performed in 998 patients. Albuminuria was measured in 1009 and NT-proBNP/hs-TnI in 933 patients. The end point was a composite of CV events. Results: The median follow-up was 4.7 years (interquartile range: 4.0-5.3), and 174 patients experienced a CV disease event. All considered markers, except hs-TnI, were significantly (P <.001) associated with the outcome: abnormal echocardiogram (hazard ratio 2.40 [1.70-3.39]), albuminuria 2.01 (1.47-2.76), abnormal ECG (2.27 [1.66-3.08]), high NT-proBNP (>150 pg/mL) 3.05 (2.11-4.40), and hs-TnI 1.12 (0.79-1.59). After adjusting for clinical variables, all remained significantly associated with the end point. However, after adjusting for each other, only NT-proBNP >150 pg/mL remained significantly associated with the end point (2.07 [1.28-3.34], P <.001). Measured by C-statistics, model performance was highest with log2 (NT-proBNP) (0.70 [0.65-0.75]) and similar to clinical variables alone (0.71 [0.67-0.76]). Combining all risk markers only resulted in a very limited increase in C-statistics (0.69 [0.64-0.74]). Conclusions: This study identified NT-proBNP over echocardiography, ECG, and albuminuria in risk prediction in patients with type 2 diabetes. The diagnostic yield in considering more than one risk marker was limited in this population.",
keywords = "albuminuria, echocardiography, electrocardiography, plasma NT-proBNP, type 2 diabetes",
author = "Nikolaj Busch and Jensen, {Magnus T.} and Goetze, {Jens P.} and Morten Schou and Tor Biering-S{\o}rensen and Thomas Fritz-Hansen and Andersen, {Henrik U.} and Tina Vilsb{\o}ll and Peter Rossing and J{\o}rgensen, {Peter G.}",
year = "2021",
doi = "10.1111/1753-0407.13172",
language = "English",
volume = "13",
pages = "754--763",
journal = "Journal of Diabetes",
issn = "1753-0393",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes

AU - Busch, Nikolaj

AU - Jensen, Magnus T.

AU - Goetze, Jens P.

AU - Schou, Morten

AU - Biering-Sørensen, Tor

AU - Fritz-Hansen, Thomas

AU - Andersen, Henrik U.

AU - Vilsbøll, Tina

AU - Rossing, Peter

AU - Jørgensen, Peter G.

PY - 2021

Y1 - 2021

N2 - Background: Diagnostic tests including echocardiography, albuminuria, electrocardiogram (ECG), high-sensitivity troponin I (hs-TnI), and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been suggested as cardiovascular (CV) risk predictors in type 2 diabetes. We studied the separate and combined prognostic yield of these risk markers. Methods: In all, 1030 patients with type 2 diabetes were recruited from specialized clinics in this prospective cohort study. Full echocardiographic evaluation was feasible in 886 patients in sinus rhythm with adequate image quality. ECG was performed in 998 patients. Albuminuria was measured in 1009 and NT-proBNP/hs-TnI in 933 patients. The end point was a composite of CV events. Results: The median follow-up was 4.7 years (interquartile range: 4.0-5.3), and 174 patients experienced a CV disease event. All considered markers, except hs-TnI, were significantly (P <.001) associated with the outcome: abnormal echocardiogram (hazard ratio 2.40 [1.70-3.39]), albuminuria 2.01 (1.47-2.76), abnormal ECG (2.27 [1.66-3.08]), high NT-proBNP (>150 pg/mL) 3.05 (2.11-4.40), and hs-TnI 1.12 (0.79-1.59). After adjusting for clinical variables, all remained significantly associated with the end point. However, after adjusting for each other, only NT-proBNP >150 pg/mL remained significantly associated with the end point (2.07 [1.28-3.34], P <.001). Measured by C-statistics, model performance was highest with log2 (NT-proBNP) (0.70 [0.65-0.75]) and similar to clinical variables alone (0.71 [0.67-0.76]). Combining all risk markers only resulted in a very limited increase in C-statistics (0.69 [0.64-0.74]). Conclusions: This study identified NT-proBNP over echocardiography, ECG, and albuminuria in risk prediction in patients with type 2 diabetes. The diagnostic yield in considering more than one risk marker was limited in this population.

AB - Background: Diagnostic tests including echocardiography, albuminuria, electrocardiogram (ECG), high-sensitivity troponin I (hs-TnI), and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been suggested as cardiovascular (CV) risk predictors in type 2 diabetes. We studied the separate and combined prognostic yield of these risk markers. Methods: In all, 1030 patients with type 2 diabetes were recruited from specialized clinics in this prospective cohort study. Full echocardiographic evaluation was feasible in 886 patients in sinus rhythm with adequate image quality. ECG was performed in 998 patients. Albuminuria was measured in 1009 and NT-proBNP/hs-TnI in 933 patients. The end point was a composite of CV events. Results: The median follow-up was 4.7 years (interquartile range: 4.0-5.3), and 174 patients experienced a CV disease event. All considered markers, except hs-TnI, were significantly (P <.001) associated with the outcome: abnormal echocardiogram (hazard ratio 2.40 [1.70-3.39]), albuminuria 2.01 (1.47-2.76), abnormal ECG (2.27 [1.66-3.08]), high NT-proBNP (>150 pg/mL) 3.05 (2.11-4.40), and hs-TnI 1.12 (0.79-1.59). After adjusting for clinical variables, all remained significantly associated with the end point. However, after adjusting for each other, only NT-proBNP >150 pg/mL remained significantly associated with the end point (2.07 [1.28-3.34], P <.001). Measured by C-statistics, model performance was highest with log2 (NT-proBNP) (0.70 [0.65-0.75]) and similar to clinical variables alone (0.71 [0.67-0.76]). Combining all risk markers only resulted in a very limited increase in C-statistics (0.69 [0.64-0.74]). Conclusions: This study identified NT-proBNP over echocardiography, ECG, and albuminuria in risk prediction in patients with type 2 diabetes. The diagnostic yield in considering more than one risk marker was limited in this population.

KW - albuminuria

KW - echocardiography

KW - electrocardiography

KW - plasma NT-proBNP

KW - type 2 diabetes

U2 - 10.1111/1753-0407.13172

DO - 10.1111/1753-0407.13172

M3 - Journal article

C2 - 33656260

AN - SCOPUS:85102555168

VL - 13

SP - 754

EP - 763

JO - Journal of Diabetes

JF - Journal of Diabetes

SN - 1753-0393

IS - 9

ER -

ID: 259054101